Media Coverage

 

click on a title or "read full article"!

2019

mission cure log horizontalRare Disease Repurposing Datathon from Elsevier and The Pistoia Alliance Reveals New Candidates for Potential Treatment of Chronic Pancreatitis
Elsevier, Feb 28, 2019

Rare Disease Day – A unique non-profit and private partnership using a datathon and an AI-powered technology platform has identified new repurposable drug candidates to treat a painful chronic disease affecting about a million people globally and for which there is no current treatment.

Elsevier, the information analytics business specializing in science and health, and The Pistoia Alliance, a global, non-profit alliance working to lower barriers to innovation in life sciences, have announced the results of a joint datathon for Drug Repurposing for Rare Diseases. The datathon, conducted in partnership with non-profit groups, Cures Within Reach and Mission: Cure, involved participants from a range of organizations including life sciences, technology and academia, and has succeeded in identifying new drug candidates for repurposing to treat chronic pancreatitis. Read the full article here.

 


economist photo“Repurposing” off-patent drugs offers big hopes of new treatments
The Economist, Feb 28, 2019

Towards the end of 2014 a 66-year-old British man named Alistair had a seizure. A scan revealed shocking news. He had an inoperable brain tumour—a glioblastoma—that was likely to kill him in a few years. Soon afterwards, he read a newspaper article suggesting that a cocktail of cheap, everyday drugs, chosen for their anti-cancer effects, had helped a patient with the same disease. His doctors were unimpressed but said: “We can’t stop you.”

Four years on Alistair is still taking this drug regimen alongside the “standard-of-care” treatment. Read the full article here.

 


forbes photoFinding New Uses For Old Drugs - A Lifeline For Rare Disease Patients
Forbes, Judy Stone, Feb 28, 2019

This is Rare Diseases Week, marking events to educate the public, legislators and industry about the needs of patients with rare diseases. It also will be the yahrzeit (anniversary of the death of a loved one) of “Rose,⁠” my first long-term patient with a rare disease. The Coalition Against Pediatric Pain (TCAPP) made the Moore Heart Award for her ability to inspire and help others, even as she struggled with her severe health problems. She was so widely beloved that Dysautonomia International created an Award for Compassionate Advocacy in her name and her family and close friends established scholarships to the dysautonomia conference. Rose and her friend “Sick Chick” kindled my awareness of some of the challenges facing the rare disease community, as well as some of the advancements that will help them. Read the full article here.

 


Steve BraunSteve Braun distinguished as Most Exceptional (Chicago Region) winner of Northwestern Mutual's 2019 Community Service Award, granted $25,000 for Cures Within Reach

February 2019

MILWAUKEE, Feb. 19, 2019 /PRNewswire/ -- From connecting families with housing and food resources to providing valuable mentorship opportunities to local youth, Northwestern Mutual financial advisors are leading impactful change in their communities across the country. Through its Foundation, the company is recognizing these efforts through its 2019 Community Service Awards program by awarding nearly $300,000 in grants to nonprofits nationwide. Read the full press release here & see why Steve chooses to donate to Cures Within Reach in a short video here!

 


PillsHow to make an old drug new again
Halo, Feb 5, 2019

Q&A with Bruce Bloom, MD, CEO of Cures Within Reach

For the past 17 years, Bruce Bloom, MD has been proselytizing the virtues of drug repurposing, a cheaper, faster and often safer way to bring more treatments to market. As leader of Cures Within Reach, he has helped fund more than 75 repurposing projects that have impacted treatments for more than a dozen diseases. Read the full Q&A here.

 


2018 ▼

MassBio Challenge WinnerCures Within Reach for Cancer wins the MassBio 2018 Petri Dish Nonprofit Pitch Challenge

November 2018

Congrats to cBio Center Scientific Research Director Laura Kleiman! Her nonprofit, Cures Within Reach for Cancer, won the MassBio 2018 Petri Dish Nonprofit Pitch Challenge. @CWR4C develops new cancer treatments using inexpensive drugs already FDA-approved for other indications. Watch the 5 minute presentation here!

 


pharmatechoutlook logoTechnology Drives and Elevates Drug Repurposing

Pharma Tech Outlook, Dr. Bruce Bloom, August 2018

Drug repurposing has been a part of therapy discovery in medicine for as long as there have been drugs- even before the arrival of commercial "drugs" - when healers first repurposed nature's compounds for medical purposes. For this article we will define repurposing as testing drugs that are already approved for human use to find new uses in new diseases.

 


ABC7 June 2018 Repurposed drug gives woman with cancer the gift of life

ABC7 Eyewitness News, June 2018

A Northwest Indiana woman told she may never get pregnant again after being diagnosed with cancer is beating the odds. She says it's all thanks to the ongoing research of drug repurposing to treat diseases with no cure. In this case, she calls it a miracle drug. While pregnant with her first child, Karrie was diagnosed with a rare blood cancer. 

 


viagra image

The Washington Post, Aimee Swartz, May 2018

When a medication being developed to treat a heart condition gave patients erections, drugmakers knew they had a winner — not for angina, but for erectile dysfunction. That drug is now known as Viagra.

 


Dana Farber Award Laura Kleiman CWR for Cancer SMALLCures Within Reach for Cancer's Laura Kleiman wins Dana-Farber's 2018 Community Service Award

Laura Kleiman, PhD, has no trouble seeking her professional passion. She pursues it everywhere – at work, at home, even in the car. Dana-Farber’s 2018 Community Service Award recipient, who will be honored at Thursday afternoon’s Martin Luther King celebration (see box), is focused on one goal: making effective cancer treatment available to as many people as possible. 

 

 

 


2017 ▼

 

logo frontonco

Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics 

Frontiers in Oncology, J. Javier Hernandez, Michael Pryszlak, Lindsay Smith, Connor Yanchus, Naheed Kurji, Vijay M. Shahani and Steven V. Molinski, November 2017

The repositioning or “repurposing” of existing therapies for alternative disease indications is an attractive approach that can save significant investments of time and money during drug development. For cancer indications, the primary goal of repurposed therapies is on efficacy, with less restriction on safety due to the immediate need to treat this patient population. This report provides a high-level overview of how drug developers pursuing repurposed assets have previously navigated funding efforts, regulatory affairs, and intellectual property laws to commercialize these “new” medicines in oncology.

 


pharmtech logo

Finding a New Purpose for an Unproven Drug

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 12, Issue 10, By Cynthia A. Challener, Oct 2017

Compared to traditional drug discovery approaches, drug repurposing, repositioning, and rescue can be faster and cheaper. Although drug repurposing has been receiving growing attention in recent years, drug companies have taken this approach, at least serendipitously, for decades.

 


Judy Hsu 2017Judy Hsu hosts Global Health Repurposing Awards ceremony

ABC7 Eyewitness News, June 2017

Honors were handed out Tuesday night for those who have made a difference in the lives of rare disease patients. The organization Cures Within Reach held its annual Global Health Repurposing Awards ceremony. ABC7 Eyewitness News' Judy Hsu served as emcee.

 


ABC HavelkaMedical treatment repurposes drug, could potentially save limbs

ABC7 Eyewitness News, June 2017

A potential medical breakthrough happening in Chicago is literally saving limbs. An experimental treatment for patients with chronic poor circulation, often brought on by heart disease or diabetes, is part of a new push for drug repurposing -- finding new cures with existing medicine.


Making New Cancer Drugs Cost-effective

PILMAN- A Tapan Ray Website on Healthcare, April 2017

The prices of new cancer drugs are increasingly becoming unsustainable across the world, and more so in India. A sizable number of poor and even middle-income patients, who spend their entire life’s savings for the treatment of this dreaded disease, is pushed towards extreme economic hardship.


Turning to Plan B in Drug Development

Laboratory Equipment, Erin O'Neill, April 2017

When scientists with the pharmaceutical company Pfizer started clinical trials in 1991 on a chemical compound named UK-92480, they aimed to show the drug’s potential therapeutic benefit for a cardiovascular condition caused by restricted blood flow to the heart muscle. Less than two years later, hope that the compound, now better known as sildenafil, could treat angina began to fade.


The trials and tribulations of repurposing metformin and other generic drugs for tuberculosis

Pharmaceutical Patent Analyst, Dr. Bruce Bloom, March 2017

There are a number of generic drugs that might be useful in treating tuberculosis, but will they ever get to the patients who need them? They might, but not without a lot of help. There are intellectual property issues, endpoint issues, cost of research issues, economic incentive issues, preclinical validation issues, “who is in charge” issues and many more. It is clear that repurposed generic drugs have the potential to make a safe, effective, quick and affordable impact on a global disease of poverty such as tuberculosis.


Cures Within Reach at DIA 2017: Good Therapies at Reasonable Cost

Driving Insights to Action, February 2017

Drug repurposing and reformulation leverage already expended costs for compounds that failed to reach the market for one disorder, to develop reformulated or repurposed drugs for a different condition in less time and with less cost. How will repurposing disrupt the current market? Where are the stress points in delivering repurposed products to patients?


WBEZ Feature: Re-purpose existing drugs for new uses

iBIO Biological, John Conrad, January 30, 2017

This morning Chicago public radio, WBEZ, featured PACT member Bruce Bloom from Cures Within Reach on their “Your Health” Segment. The segment started off discussing the antiparasitic drug mebendazole, and the current research being conducted at John’s Hopkins on the drugs effectiveness in animal models of aggressive brain tumors, including advanced gliomas and medulloblastomas.


If An Anti-Parasitic Drug Fights Cancer, Will It Remain Affordable?

NPR's Morning Edition, Allison Aubrey, January 2017

One of the most effective and affordable anti-parasitic medicines is being researched for potential cancer-fighting properties. It's part of a movement to re-purpose existing drugs for new uses. Listen Here!


chalkboard scientistRepurposing Existing Drugs for New Indication

The Scientist, Anna Azvolinsky, January 2017

An entire industry has sprung up around resurrecting failed drugs and recycling existing compounds for novel indications. 


2016 ▼

A Place to Teach Old Drugs New Tricks

One Health of a Life: Deborah Collyar, Guest blog post by Dr. Bruce Bloom & Dr. Clare Thibodeaux, September 2016

Due to popular demand, former blog guests Bruce Bloom, and Clare Thibodeaux from Cures Within Reach have returned with another post. This time, they explain how they bring researchers, older drugs, and new funders together to come up with new solutions for patients. Disclosure: I am a member of their Advisory Board, and think this concept is brilliant!


Drug Repurposing and Repositioning: Making New Out of Old

DCAT Value Chain Insights, Patricia Van Arnum, July 2016

Given the high cost of new drug development, pharmaceutical companies, researchers, and other organizations are looking for innovative ways to reduce time and costs. Drug repurposing and repositioning hold some answers.


675A9686 258Global Health Repurposing Awards featured on WGN News

WGN Web Desk & Micah Mattere, June 2016

 

 


Generic Drug Repurposing Clinical Trials

Applied Clinical Trials, Bruce Bloom, JD, DDS, June 2016

There are over 7,000 “unsolved” diseases for which patients have no universally successful treatment. There are also thousands of generic drugs that can be repurposed to help these patients. Built on knowledge from scientific discoveries, anecdotal evidence, and/or bioinformatics, generic drug repurposing research can often lead to quick and affordable development of “new” medical solutions.


Repurposing Social Impact Bonds for Medicine

Stanford Social Innovation Review, Bruce Bloom, April 2016

Around 500 million people globally suffer from one of 7,000 diseases that lack a known, effective treatment. But new drugs developed by the pharmaceutical industry address only 10 to 30 additional diseases each year. At this rate, it would take between 250 and 700 years to find treatments for them all!


healthcare wordle w pillsHow to Solve Diseases with Existing Drugs

One Health of a Life: Deborah Collyer, Guest blog post by Dr. Bruce Bloom, Amy Conn, and Dr. Clare Thibodeaux, April 2016

Currently more than 500 million people worldwide suffer from diseases that lack effective treatments. As a result, global health care costs are growing and patients are suffering. Yet new drug discovery can take 10-15 years and can cost over $2 billion. This process is too long and costly for many patients who needs a solution today.


A New Economic Solution to Drive Cures to Patients

Blog Talk Radio, Pharma Talk Radio, April 2016

Generic drugs can be repurposed to create effective treatments in unsolved diseases. However, there is no economic incentive for industry to pay for a clinical validation and regulatory approval process for most generic drug repurposing because it will not achieve the necessary ROI.


BB Med CityCures Within Reach: “Creating the opposite of Valeant"

Med City News, Meghana Keshavan, April 2016

In the wake of all the price gouging antics we’ve seen at Valeant Pharmaceuticals and Turing Pharmaceuticals, Bruce Bloom’s Cures Within Reach provides a breath of fresh, philanthropic air.

The organization’s all about generic drugs – but unlike, say, Martin Shkreli, Bloom’s big idea is to repurpose existing drugs and lessen the overall costs of healthcare. It’s reliant on the idea of a government that pays industry for measurable improvements in public health – which, in Cures Within Reach’s case, involve the treatment of rare diseases.


MedCity INVEST Announces Keynote Talks Focusing on the Role of Venture Capital, Social Impact Investing and Technology and Healthcare Investing

MedCity News, Chris Seper, March 2016

At MedCity INVEST, active investors connect with corporate business development executives to facilitate investment opportunities with over 40 of the most promising healthcare start-ups that span the biotech, medical device, digital health, diagnostics, pharma, and regenerative medicine sectors.


Group Aims to Accelerate Repurposing of Drugs to Treat Rare Disease

Global Genes RARECast with Daniel Levine, January 2016

The high cost and long time it takes to develop drugs has people looking for alternative strategies for finding new treatments. One such approach is repurposing—finding new uses for already approved drugs. This is particularly compelling for rare diseases where small patient populations can serve as a disincentive to drug developers and the need for therapeutics is largely unmet. We spoke to Bruce Bloom, president and chief science officer of Cures Within Reach, which launched the crowdsourcing platform CureAccelerator to fund repurposing research for rare diseases.


2015 ▼

Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance

Assay and Drug Development Technologies, Volume 13 Issue 10, Dr. Bruce E. Bloom, December 2015

Repurposing research improves patient lives by taking drugs approved for one disease and clinically testing them to create a treatment for a different disease. Repurposing drugs that are generic, inexpensive, and widely available and that can be taken in their current dosage and formulation in the new indication provide a quick, affordable, and effective way to create “new” treatments.


Cures Within Reach Calls for 100 Drug Repurposing Projects

Clinical Informatics News, Allison Proffitt, December 2015

For severely ill children with a rare disease called autoimmune lymphoproliferative syndrome (ALPS), dead white blood cells build up in the organs instead of being broken down normally. But two pills a day of a drug approved for use after kidney transplants gives some total remission of their disease.


Voyage of Rediscovery

PharmaTimes Magazine, George Underwood, November/December 2015

The use of approved, well-known medicines to treat patients with entirely different conditions is a tried-and-tested formula for pharma companies, even when the discoveries are largely serendipitous. Using prostate-shrinking finasteride in hair regrowth, beta-blocker propranolol in infants with abnormal blood vessels and cancer-beating bevacizumab in age-related macular degeneration were all strokes of luck that proved highly effective.


 

 

Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*

*required

If the link above doesn't work, please contact our Admin support at admin@cureswithinreach.org with your Full Name and Email Address to sign up!

 

Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

info@cureswithinreach.org

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.

 

Thursday the 14th. Copyright 2018 Cures Within Reach.